Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Transplant-Associated Thrombotic Microangiopathy
NCT03252925Phase 3Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Incidence of Transplant-Associated Thrombotic Microangiopathy at 100 days. Started Nov 2017; status: completed.
02
Drugs
acetylcysteine
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NCT03252925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252925.